Soligenix (SNGX.OB) Inks Agreement with University of Colorado to Advance Vaccine Technology

QualityStocks would like to highlight Soligenix, Inc. (OTCBB: SNGX), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as vaccines for certain bioterrorism agents.

In the company’s news yesterday,

Soligenix announced it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology to develop subunit vaccines with long-term stability, including stability at elevated temperatures.

Soligenix’s technology is the subject of several United States and foreign patent applications involving the use of adjuvants in combination with vaccines designed to resist thermal inactivation. The company has been developing this technology under an agreement from CU supported by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID).

The company said the license agreement expands scope for thermostable vaccines for biodefense in addition to potential vaccine indications. Soligenix’s stabilization technology is being used to advance RiVax™, its subunit vaccine against ricin toxin, as well as a subnit vaccine for anthrax prevention.

“The achievement of extended stability as well as stability under elevated temperature would represent a significant step forward in vaccine technology. These properties are not shared with conventional vaccines that require refrigeration,” Robert N. Brey, PhD, chief scientific officer of Soligenix stated in the press release. “Lack of long-term stability is a significant problem in vaccines for use in emergency situations and especially for vaccines used in the developing world where the cold storage chain is difficult to maintain. Further, this novel thermostability technology has the potential to allow us to expand our vaccine business into the development of countermeasures against other more common infectious diseases.”

Theodore Randolph, PhD, professor of Chemical and Biological Engineering at CU-Boulder, noted the importance of vaccines in the overall healthcare market, and detailed issues that the stabilization technology has the potential to address.

“Vaccines are a valuable part of our healthcare arsenal, providing great benefit per dollar spent,” Dr. Randolph stated. “Most current vaccines, however, require carefully controlled cold storage conditions to retain their potency and safety. This adds cost and greatly complicates strategies for their use, especially in public health emergencies or in developing countries. We are pleased that Soligenix has licensed our technology, which offers the potential to create vaccine formulations whose enhanced thermostability allows them to be stockpiled and delivered to patients with much less stringent temperature control requirements.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.